NASDAQ:HALO • US40637H1095
View the latest analyst price targets, stock forecast, EPS estimates, revenue projections, revisions, full estimates, rating distribution and upgrades/downgrades for HALOZYME THERAPEUTICS INC (HALO).
| Date | Firm | Action | From → To |
|---|---|---|---|
| 2026-02-19 | Benchmark | Maintains | Buy -> Buy |
| 2026-02-19 | Wells Fargo | Maintains | Equal-Weight -> Equal-Weight |
| 2026-01-08 | TD Cowen | Maintains | Buy -> Buy |
| 2025-12-19 | HC Wainwright & Co. | Reiterate | Buy -> Buy |
| 2025-11-28 | HC Wainwright & Co. | Reiterate | Buy -> Buy |
| 2025-11-18 | Goldman Sachs | Maintains | Neutral -> Neutral |
| 2025-11-04 | Citizens | Maintains | Market Outperform -> Market Outperform |
| 2025-10-27 | JP Morgan | Maintains | Neutral -> Neutral |
| 2025-10-20 | Morgan Stanley | Maintains | Overweight -> Overweight |
| 2025-10-15 | HC Wainwright & Co. | Reiterate | Buy -> Buy |
| 2025-10-14 | Leerink Partners | Upgrade | Underperform -> Market Perform |
| 2025-10-02 | HC Wainwright & Co. | Maintains | Buy -> Buy |
| 2025-09-24 | Benchmark | Maintains | Buy -> Buy |
| 2025-09-22 | HC Wainwright & Co. | Maintains | Buy -> Buy |
| 2025-08-18 | Morgan Stanley | Maintains | Overweight -> Overweight |
| 2025-08-07 | JP Morgan | Maintains | Neutral -> Neutral |
| 2025-08-06 | JMP Securities | Maintains | Market Outperform -> Market Outperform |
| 2025-08-06 | Morgan Stanley | Upgrade | Equal-Weight -> Overweight |
| 2025-08-06 | HC Wainwright & Co. | Maintains | Buy -> Buy |
| 2025-07-16 | JP Morgan | Maintains | Neutral -> Neutral |
| 2025-05-29 | HC Wainwright & Co. | Reiterate | Buy -> Buy |
| 2025-05-14 | Morgan Stanley | Downgrade | Overweight -> Equal-Weight |
| 2025-05-13 | Leerink Partners | Downgrade | Market Perform -> Underperform |
| 2025-05-07 | Wells Fargo | Maintains | Equal-Weight -> Equal-Weight |
| 2025-04-25 | HC Wainwright & Co. | Reiterate | Buy -> Buy |
| 2023 | 2024 | 2025 | 2026 | 2027 | 2028 | 2029 | 2030 | 2031 | 2032 | 2033 | ||
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue YoY % growth | 829.253M 25.63% | 1.015B 22.44% | 1.397B 37.55% | 1.791B 28.24% | 2.016B 12.56% | 2.189B 8.58% | 1.956B -10.64% | 1.81B -7.46% | 1.726B -4.64% | 1.486B -13.90% | 1.36B -8.48% | |
| EBITDA YoY % growth | 424.93M 25.35% | 632.787M 48.92% | 904.344M 42.91% | 1.194B 32.03% | 1.44B 20.60% | 1.58B 9.72% | 1.502B -4.94% | 1.322B -11.98% | 1.321B -0.08% | 1.137B -13.93% | 875.98M -22.96% | |
| EBIT YoY % growth | 340.074M 17.51% | 551.475M 62.16% | 816.293M 48.02% | 1.078B 32.06% | 1.333B 23.65% | 1.459B 9.45% | 1.122B -23.10% | 996.54M -11.18% | 821.1M -17.60% | 518.16M -36.89% | 519.18M 0.20% | |
| Operating Margin | 41.01% | 54.32% | 58.45% | 60.19% | 66.12% | 66.65% | 57.36% | 55.06% | 47.57% | 34.87% | 38.18% | |
| EPS YoY % growth | 2.78 25.23% | 4.23 52.16% | 4.13 -2.36% | 8.18 97.97% | 10.04 22.82% | 10.53 4.82% | 9.68 -8.04% | 8.74 -9.75% | 8.19 -6.25% | 6.51 -20.49% | 5.67 -13.00% |
All data in USD
| Q1 / 26 | Q2 / 26 | Q3 / 26 | Q4 / 26 | Q1 / 27 | Q2 / 27 | Q3 / 27 | Q4 / 27 | |
|---|---|---|---|---|---|---|---|---|
| EPS Q2Q % growth | 1.56 40.59% | 1.85 20.41% | 2.25 30.70% | 2.59 1,177.80% | 2.06 31.81% | 2.36 27.43% | 2.50 11.16% | 2.75 6.47% |
| Revenue Q2Q % growth | 366.05M 38.20% | 410.36M 25.99% | 477.25M 34.72% | 540.24M 19.58% | N/A | N/A | N/A | N/A |
| EBITDA Q2Q % growth | 223.04M 37.69% | 257.46M 5.78% | 327.07M 17.11% | 371.31M 8.43% | N/A | N/A | N/A | N/A |
| EBIT Q2Q % growth | 203.19M 43.56% | 238.58M 17.85% | 291.21M 33.63% | 335.12M 31.73% | N/A | N/A | N/A | N/A |
All data in USD
15 analysts have analysed HALO and the average price target is 86.59 USD. This implies a price increase of 32.48% is expected in the next year compared to the current price of 65.36.
HALOZYME THERAPEUTICS INC (HALO) will report earnings on 2026-05-12.
The consensus EPS estimate for the next earnings of HALOZYME THERAPEUTICS INC (HALO) is 1.56 USD and the consensus revenue estimate is 366.05M USD.
The number of analysts covering HALOZYME THERAPEUTICS INC (HALO) is 15.